DE69826717D1 - Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii - Google Patents

Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii

Info

Publication number
DE69826717D1
DE69826717D1 DE69826717T DE69826717T DE69826717D1 DE 69826717 D1 DE69826717 D1 DE 69826717D1 DE 69826717 T DE69826717 T DE 69826717T DE 69826717 T DE69826717 T DE 69826717T DE 69826717 D1 DE69826717 D1 DE 69826717D1
Authority
DE
Germany
Prior art keywords
obesity
target
type
treating atherosclerosis
diabetis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69826717T
Other languages
English (en)
Other versions
DE69826717T2 (de
Inventor
Itzik Harosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ObeTherapy Biotechnology SAS
Original Assignee
ObeTherapy Biotechnology SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObeTherapy Biotechnology SAS filed Critical ObeTherapy Biotechnology SAS
Application granted granted Critical
Publication of DE69826717D1 publication Critical patent/DE69826717D1/de
Publication of DE69826717T2 publication Critical patent/DE69826717T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE69826717T 1997-12-30 1998-12-28 Target zur behandlung von arteriosklerose, fettleibigkeit und diabetes typ ii Expired - Lifetime DE69826717T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9716655A FR2773079B1 (fr) 1997-12-30 1997-12-30 Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
FR9716655 1997-12-30
PCT/FR1998/002883 WO1999035257A1 (fr) 1997-12-30 1998-12-28 Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii

Publications (2)

Publication Number Publication Date
DE69826717D1 true DE69826717D1 (de) 2004-11-04
DE69826717T2 DE69826717T2 (de) 2006-02-23

Family

ID=9515258

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69826717T Expired - Lifetime DE69826717T2 (de) 1997-12-30 1998-12-28 Target zur behandlung von arteriosklerose, fettleibigkeit und diabetes typ ii

Country Status (7)

Country Link
US (1) US6942967B1 (de)
EP (1) EP1042463B1 (de)
AT (1) ATE278014T1 (de)
AU (1) AU1971399A (de)
DE (1) DE69826717T2 (de)
FR (1) FR2773079B1 (de)
WO (1) WO1999035257A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6910100A (en) * 1999-08-18 2001-03-13 Lawrence Chan Apolipoprotein b mrna-specific ribozyme
CA2439472A1 (en) * 2001-02-27 2002-09-06 University Of Rochester Methods and compositions for modifying apolipoprotein b mrna editing
AU2003257181A1 (en) * 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
CA2537798A1 (en) * 2003-09-03 2005-03-17 University Of Rochester Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
WO2005115410A2 (en) * 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
FR2870855A1 (fr) * 2004-05-27 2005-12-02 Obe Therapy Biotechnology Soc Procede de criblage a haut debit pour l'identification de molecules inhibitrices de l'activite d'enzymes d'edition
KR100905419B1 (ko) 2008-09-11 2009-07-02 연세대학교 산학협력단 세스퀴테르펜 유도체의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2762014B1 (fr) 1997-04-10 1999-06-04 Itzik Harosh Utilisation d'apobeg1 ou des proteines associees, ou des genes responsables de la maladie d'andersons comme cible de traitement de l'atherosclerose et de l'obesite et techniques associees de clonage et de criblage d'inhibiteurs

Also Published As

Publication number Publication date
FR2773079B1 (fr) 2002-05-17
EP1042463A1 (de) 2000-10-11
DE69826717T2 (de) 2006-02-23
ATE278014T1 (de) 2004-10-15
FR2773079A1 (fr) 1999-07-02
EP1042463B1 (de) 2004-09-29
US6942967B1 (en) 2005-09-13
AU1971399A (en) 1999-07-26
WO1999035257A1 (fr) 1999-07-15

Similar Documents

Publication Publication Date Title
Gordon et al. The primary translation product of rat intestinal apolipoprotein AI mRNA is an unusual preproprotein.
Bertenshaw et al. Marked differences between metalloproteases meprin A and B in substrate and peptide bond specificity
Conover et al. Cleavage Analysis of Insulin-like Growth Factor (IGF)-dependent IGF-binding Protein-4 Proteolysis and Expression of Protease-resistant IGF-binding Protein-4 Mutants (∗)
DE69834267D1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
BR9814276A (pt) Antìgenos de superfìcie
ATE302267T1 (de) Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
ATE242003T1 (de) Enzyme zur behandlung von diabetes mellitus typ i
FI965031A (fi) Sieni, jossa AreA-geeni on muunnettu, ja Aspergillus oryzaesta peräisin oleva areA-geeni
ATE513917T1 (de) Bakterielle expression von proteaseinhibitoren und varianten davon
ATE510851T1 (de) Auf peptiden basierende immunisierungstherapie zur behandlung von atherosklerose
ATE499382T1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
ATE404217T1 (de) Therapie mit lipoproteinlipase (lpl) variant
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
ATE500266T1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
DE69826717D1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
ATE323763T1 (de) Dna & protein bindende miniatur proteine
MORADIAN-OLDAK et al. Identification of a novel proteinase (ameloprotease-I) responsible for the complete degradation of amelogenin during enamel maturation
HUP0001458A2 (hu) Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
SE9701228D0 (sv) Rekombinanta protein-C-och protein-S-varianter
DE69613685D1 (de) D-aminosäure-oxidase kodierendes dns-fragment
DK0616642T3 (da) Hidtil ukendte thrombininhibitoriske proteiner fra landblodigler
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
NO20023914D0 (no) Preparater for anvendelse ved regulering av Parkin- genaktiviteten
TR200002611T2 (tr) Beta-lipotropin ve kullanımları

Legal Events

Date Code Title Description
8364 No opposition during term of opposition